Recurrent or Refractory Disease After Standard Therapies
2 clinical trials · Condition
◉ Watch Recurrent or Refractory Disease After Standard Therapies
| Record | Firm | Date |
|---|---|---|
| Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16) pt2 (NCT07617753) | Beijing Biotech | 2026-03-02 |
| Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16) (NCT07480954) | Beijing Biotech | 2026-02-04 |
Track Recurrent or Refractory Disease After Standard Therapies automatically
Every clearance here is in the API, with alerts when new ones post.